Who is sponsoring NCT03120936?

NCT03120936 is sponsored by Public Health Foundation Enterprises, Inc..

What drugs are being tested in NCT03120936?

Interventions in NCT03120936: Emtricitabine / Tenofovir Disoproxil Oral Tablet, PrEP support.

What condition does NCT03120936 study?

NCT03120936 studies Transgender Persons, Pre-Exposure Prophylaxis.

Is NCT03120936 still recruiting?

NCT03120936 is currently completed. Last updated 21 April 2021.

Last reviewed 2021-04-21 · How we verify

NCT03120936

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community

Completed Phase 4 Last updated 21 April 2021

What this trial tests

Phase 4 trial testing Emtricitabine / Tenofovir Disoproxil Oral Tablet in Transgender Persons in 158 participants. Completed in 1 December 2020.

Timeline

8 August 2017

Primary endpoint
27 August 2020

1 December 2020

Quick facts

Lead sponsor	Public Health Foundation Enterprises, Inc.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	158
Start date	8 August 2017
Primary completion	27 August 2020
Estimated completion	1 December 2020
Sites	5 locations across United States

Drugs / interventions tested

Emtricitabine / Tenofovir Disoproxil Oral Tablet — full drug profile →
PrEP support

Conditions studied

Transgender Persons — all drugs for Transgender Persons →
Pre-Exposure Prophylaxis — all drugs for Pre-Exposure Prophylaxis →

Sponsor

Public Health Foundation Enterprises, Inc.

Who can join

18 and older, any sex, with Transgender Persons or Pre-Exposure Prophylaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be provided Truvada to take orally once daily as PrEP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.
Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, et al · · 2019 · cited 122× · PMID 30239620 · DOI 10.1093/cid/ciy810

Verify or expand the search:

Other trials of Emtricitabine / Tenofovir Disoproxil Oral Tablet

Trials testing the same drug.

NCT05458765 — Project Engage: Oral PrEP Acceptability · Phase 2 · completed
NCT04329442 — Accelerated PrEP Access for Black MSM and TW · NA · withdrawn
NCT03771638 — DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men · Phase 4 · completed
NCT03387462 — DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence · Phase 4 · completed

Other recruiting trials for Transgender Persons

Currently open trials in the same condition.

NCT06177600 — TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults · NA · recruiting
NCT06832514 — Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons · Phase 4 · recruiting
NCT05924217 — Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France · active not recruiting
NCT05116293 — Effect of Testosterone Treatment on Drug Metabolism and Transport · active not recruiting

Other Public Health Foundation Enterprises, Inc. trials

Trials by the same sponsor.

NCT07528573 — HIV Prevention and Care Engagement in Nepal · NA · completed
NCT06631365 — PrEPsmart 2-1-1 Pilot · Phase 2 · recruiting
NCT07146139 — MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women · NA · terminated
NCT05196009 — mHealth Systems Navigation- Breaking Systems Barriers for Trans Women Living With HIV · NA · unknown
NCT03965221 — Comparison of Men's Prevention Apps to Research Efficacy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03120936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Public Health Foundation Enterprises, Inc.
Last refreshed: 21 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03120936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing